Table 2.
Reported adverse events of anti-intereukin-1 agents in clinical use for pericarditis
| Anakinra14,17,23 | Rilonacept15,16 | Canakinumab24–27,29 | |
|---|---|---|---|
| Severe side effectsa | <1–4% | Up to 6% | Up to 12% |
| Injection site reactions | 38–95% | 34–60% | <10% |
| Infections | 3–5% | Variable* | 3–7% |
| Elevation of transaminases | 3–14% | Up to 4% | 2–4% |
| Arthralgias, myalgias | 6–8% | Up to 12% | 2% |
| Elevation of blood lipids | Possibleb | Up to 8% | NR |
| Neutropenia or leukopenia | 1–3% | Possiblea | <1% |
| Permanent discontinuation due to adverse events | 3% | 3% | NR |
NR, not reported.
*
Depending on treatment times up to 40% (RHAPSODY trial) and usually mild to moderate.
a
Reported severe side effects included an ischaemic optic neuropathy in the AIRTRIP trial14 that was judged to be probably unrelated to treatment; skin reactions and intolerable arthralgias and myalgias leading to drug discontinuation were reported in the IRAP registry17; squamous-cell carcinoma, alopecia, extrinsic allergic alveolitis, erythema, and hypersensitivity reactions were reported in the RHAPSODY trial.16 Fatal infections and sepsis were the main adverse events reported in the CANTOS trial.27
b
Adverse events reported without a precise quantification.